Clinical trials: Kidney Cancer, open to volunteers
Renal Cell Cancer
WIRE - Novel Treatments in Renal Cell Cancer
Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when different IMPs are given as monotherapy or as combination therapy.
- Trial name
- WIRE (NCT03741426)
- Testing
- Olaparib, Cediranib, Volrustomig
- Where
- 7 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- CCTU- Cancer Theme
Kidney Cancers
Clinical Application of CAIX-Targeted PET Imaging in Tumors
According to the 2020 global cancer statistics, renal carcinoma ranks as the fourteenth most common malignant tumor worldwide. In 2020, there were 431,288 new cases and 179,368 deaths from renal cancer, and both the incidence and…
- Trial name
- NCT07590310
- Testing
- Each patient will undergo 68Ga/18F-CAIX-LT-BCH PET/CT imaging, with an administered radioactive dose of approximately 0.05-0.1 mCi/kg.
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University Cancer Hospital & Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumor Malignancies, Hematologic Cancer
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Conditions
- Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer
- Trial name
- NCT07039474
- Testing
- 18F-G1
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Multiple Myeloma, Acute Kidney Injury
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.
- Conditions
- Multiple Myeloma, Acute Kidney Injury, Hemodiafiltration With Ultrafiltrate Regeneration (HFR)
- Trial name
- NCT05429515
- Testing
- HFR-SUPRA, hemodialysis, Chemotherapy
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Lung Neoplasms
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark comparing the treatment recommendations of six frontier large language models (LLMs)…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Urologic Neoplasms, Prostatic Neoplasms
- Trial name
- BEACON (NCT07739121)
- Testing
- Multidisciplinary tumour boards, Frontier large language models
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Renal Cell Carcinoma (aRCC)
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Introduction: This document explains a clinical research study conducted at Peking Union Medical College Hospital. The study aims to evaluate a new combination treatment - Envafolimab (an immunotherapy) and Axitinib (a targeted…
- Trial name
- NCT07159191
- Testing
- Envafolimab Injection, Axitinib Tablets
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Carcinoma, Renal Cell
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy.
- Trial name
- NCT05287945
- Testing
- Orellanine
- Where
- 10 sites in United States, France and 3 more
- Volunteers
- 75 people
- Sponsor
- Oncorena AB
Renal Tumor, Renal Cell Carcinoma
PET/MR for Characterization of Renal Masses (RMs)
The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer.
- Conditions
- Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
- Trial name
- NCT06076538
- Testing
- 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Kidney Injury, Cancer
Cisplatin Induced Kidney Toxicity
Cisplatin (CisP) is a chemotherapeutic agent used to treat head and neck and lung cancer in adults and over 15 different pediatric cancers.
- Trial name
- ACCENT (NCT04442516)
- Testing
- Questionnaire, sampling of blood, urine and saliva
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- The Hospital for Sick Children
Clear Cell Renal Cell Carcinoma
A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma is the most common type of kidney cancer. Although new treatments such as immune checkpoint inhibitors and targeted therapies have improved outcomes for many patients, some patients with advanced…
- Trial name
- CM-BA-9 (NCT07865832)
- Testing
- CM-BA-9
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Liangyou Gu
Kidney Neoplasm, Nephrectomy
Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and Stability
This study is a retrospective and prospective comparative study evaluating the efficacy, safety, and stability of the surgical navigation system 'RUS NE' in robot-assisted partial nephrectomy.
- Conditions
- Kidney Neoplasm, Nephrectomy, Surgical Navigation Systems, Renal Mass
- Trial name
- HTK_002 (NCT06945640)
- Testing
- RUS NE
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Hutom Corp
Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
Genitourinary Tumors With Sacituzumab Tirumotecan
RINGQUEST is a Phase 2, open-label, single arm, basket, investigator-initiated clinical trial of sacituzumab tirumotecan in patients with: Cohort 1: papillary renal carcinoma (pRCC).
- Trial name
- RINGQUEST (NCT07716917)
- Testing
- Sacituzumab Tirumotecan (SKB264)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Adult Solid Tumor, Advanced Solid Tumor
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic…
- Conditions
- Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT05752552
- Testing
- DO-2
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 55 people
- Sponsor
- DeuterOncology
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Kidney Cancer
Protocol Active Surveillance Small Renal Masses (SRMs)
Prospective study of active surveillance, non-randomized, multicentric, in asymptomatic patients over the age of 50 years, not affected by other tumors, with occasional diagnosis of single monolateral solid renal mass equal to or…
- Trial name
- NCT03804320
- Testing
- Active Surveillance
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS San Raffaele
Renal Cell Carcinoma (RCC)
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
This is a prospective cohort study aimed at clarifying the predictive value of MRD for postoperative DFS and OS in high-risk recurrent renal cell carcinoma patients who have undergone radical nephrectomy and received adjuvant…
- Trial name
- NCT07657325
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Second Hospital